A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Financial Summary
| Share Statistics | HIND | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13.7 | $593.0 | 8% |
|
| Shares Out (Mil) | 7.0 | 42.7 | 17% |
|
| Institutional Ownership | 38.1% | 83.7% | 16% |
|
| Float (Mil) | 3.6 | 45.1 | 9% |
|
| Beta | na | 0.72 | na |
|
| Avg Daily Volume (000s) | 33 | 382 | 24% |
|
| Price Change (52-week) |
(68.7%) | 64.3% | 10% |
|
| Growth | HIND | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | HIND | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $317 | 0% |
|
| Net Income (TTM) (Mil) | ($11) | ($11) | 28% |
|
| EPS (TTM) | ($1.611) | ($0.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $10 | $493 | 7% |
|
| Valuation | HIND | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.27 | 2.48 | 56% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | HIND | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.7% | 69.4% | 65% |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (209.4%) | (22.4%) | 2% |
|
| ROE | na | (21.8%) | na |
|
| Liabilities to Assets | 20.3% | 32.4% | 13% |
|
| F-Score | 2 | 3 | na |
|
Vyome Holdings, Inc. did not pass any screens on 9/22/2026.
